Legato Capital Management LLC Acquires 5,962 Shares of Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN)

Legato Capital Management LLC boosted its holdings in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) by 27.8% during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 27,434 shares of the specialty pharmaceutical company’s stock after acquiring an additional 5,962 shares during the period. Legato Capital Management LLC’s holdings in Supernus Pharmaceuticals were worth $992,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other large investors have also added to or reduced their stakes in SUPN. Barclays PLC increased its position in Supernus Pharmaceuticals by 88.3% during the 3rd quarter. Barclays PLC now owns 108,788 shares of the specialty pharmaceutical company’s stock worth $3,393,000 after buying an additional 51,005 shares during the period. Segall Bryant & Hamill LLC bought a new position in Supernus Pharmaceuticals during the 3rd quarter worth $791,000. Geode Capital Management LLC increased its position in Supernus Pharmaceuticals by 5.3% during the 3rd quarter. Geode Capital Management LLC now owns 1,482,051 shares of the specialty pharmaceutical company’s stock worth $46,218,000 after buying an additional 74,438 shares during the period. Franklin Resources Inc. increased its position in Supernus Pharmaceuticals by 7.6% during the 3rd quarter. Franklin Resources Inc. now owns 29,981 shares of the specialty pharmaceutical company’s stock worth $987,000 after buying an additional 2,121 shares during the period. Finally, JPMorgan Chase & Co. increased its position in Supernus Pharmaceuticals by 40.6% during the 3rd quarter. JPMorgan Chase & Co. now owns 253,396 shares of the specialty pharmaceutical company’s stock worth $7,901,000 after buying an additional 73,118 shares during the period.

Analyst Upgrades and Downgrades

Several research analysts have weighed in on SUPN shares. Piper Sandler reiterated a “neutral” rating on shares of Supernus Pharmaceuticals in a research report on Friday, October 18th. Cowen reiterated a “buy” rating on shares of Supernus Pharmaceuticals in a research report on Friday, October 18th. Finally, Cantor Fitzgerald began coverage on Supernus Pharmaceuticals in a research report on Monday, January 6th. They set an “overweight” rating and a $57.00 price objective on the stock.

Supernus Pharmaceuticals Stock Performance

Shares of NASDAQ SUPN opened at $39.53 on Friday. Supernus Pharmaceuticals, Inc. has a 52 week low of $25.53 and a 52 week high of $40.28. The stock has a market capitalization of $2.18 billion, a P/E ratio of 36.94 and a beta of 0.90. The stock’s fifty day moving average is $37.50 and its 200 day moving average is $35.01.

Insider Buying and Selling

In related news, VP Padmanabh P. Bhatt sold 700 shares of the firm’s stock in a transaction on Tuesday, January 28th. The stock was sold at an average price of $39.62, for a total value of $27,734.00. Following the transaction, the vice president now owns 10,149 shares in the company, valued at approximately $402,103.38. This trade represents a 6.45 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. 9.30% of the stock is owned by company insiders.

Supernus Pharmaceuticals Company Profile

Supernus Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. The company's commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; and Oxtellar XR, an extended release oxcarbazepine for the monotherapy treatment of partial onset seizures in adults and children between 6 to 17 years of age.